Initial Public Offering
Baird served as co-manager on this offering.
AboutAxovant Sciences Ltd. (“Axovant” or “the Company”) (NYSE:AXON) recently completed an initial public offering of 24,150,000 common shares at a price of $15.00 per share generating gross proceeds of approximately $362.3 million. The Company intends to use the net proceeds from the offering for the clinical development of its product candidate, RVT-101, and any remaining proceeds for working capital and general corporate purposes.
Axovant is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The Company’s goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function. Axovant is headquartered in Hamilton, Bermuda.
For additional information about this transaction, please contact:
- June 2015
- Axovant Sciences Ltd.
- Target Location
- North America